Wright Investors Service Inc. grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 249.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 44,960 shares of the biopharmaceutical company’s stock after buying an additional 32,110 shares during the period. Gilead Sciences accounts for about 1.2% of Wright Investors Service Inc.’s holdings, making the stock its 22nd largest holding. Wright Investors Service Inc.’s holdings in Gilead Sciences were worth $3,037,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Dimensional Fund Advisors LP boosted its stake in shares of Gilead Sciences by 1.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 5,129,197 shares of the biopharmaceutical company’s stock valued at $320,822,000 after purchasing an additional 51,905 shares during the period. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Gilead Sciences during the first quarter valued at approximately $2,305,000. CAPROCK Group Inc. boosted its stake in shares of Gilead Sciences by 14.2% during the first quarter. CAPROCK Group Inc. now owns 5,457 shares of the biopharmaceutical company’s stock valued at $355,000 after purchasing an additional 678 shares during the period. DeDora Capital Inc. boosted its stake in shares of Gilead Sciences by 29.9% during the first quarter. DeDora Capital Inc. now owns 14,632 shares of the biopharmaceutical company’s stock valued at $951,000 after purchasing an additional 3,370 shares during the period. Finally, American National Bank boosted its stake in shares of Gilead Sciences by 2.0% during the first quarter. American National Bank now owns 47,974 shares of the biopharmaceutical company’s stock valued at $3,119,000 after purchasing an additional 929 shares during the period. 78.87% of the stock is owned by institutional investors.
Gilead Sciences stock traded up $0.39 on Thursday, hitting $63.51. 1,895,115 shares of the stock traded hands, compared to its average volume of 6,220,770. The company has a debt-to-equity ratio of 1.13, a quick ratio of 3.67 and a current ratio of 3.76. The stock has a market capitalization of $81.03 billion, a price-to-earnings ratio of 10.33, a P/E/G ratio of 3.04 and a beta of 1.16. The firm has a fifty day moving average of $66.33. Gilead Sciences, Inc. has a 1 year low of $60.32 and a 1 year high of $79.61.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 27th. Shareholders of record on Friday, September 13th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 3.97%. The ex-dividend date of this dividend is Thursday, September 12th. Gilead Sciences’s dividend payout ratio is currently 40.98%.
A number of analysts have recently weighed in on GILD shares. BidaskClub lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, June 5th. Evercore ISI reissued a “buy” rating on shares of Gilead Sciences in a research note on Friday, May 17th. Wells Fargo & Co raised Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $68.00 to $88.00 in a research note on Monday, July 15th. JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $85.00 price target on shares of Gilead Sciences in a research note on Wednesday, July 31st. Finally, Jefferies Financial Group set a $95.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research note on Monday, July 15th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $82.29.
In other Gilead Sciences news, EVP Brett A. Pletcher sold 5,816 shares of the firm’s stock in a transaction on Tuesday, June 18th. The stock was sold at an average price of $68.75, for a total transaction of $399,850.00. Following the completion of the transaction, the executive vice president now owns 27,198 shares of the company’s stock, valued at $1,869,862.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Brett A. Pletcher sold 7,200 shares of the firm’s stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $65.07, for a total value of $468,504.00. Following the transaction, the executive vice president now directly owns 34,398 shares of the company’s stock, valued at approximately $2,238,277.86. The disclosure for this sale can be found here. Company insiders own 0.20% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
See Also: Trading Ex-Dividend
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.